MetaVia ( (MTVA) ) just unveiled an announcement.
On April 22, 2025, MetaVia Inc. reported additional positive top-line results from the multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a dual receptor agonist for obesity treatment. The trial demonstrated a dose-dependent response in body weight reduction and significant differences in BMI compared to placebo, without any drug-induced cardiovascular effects. The results suggest DA-1726’s potential as a best-in-class obesity treatment, with a robust safety profile and promising efficacy, particularly in higher doses. MetaVia plans to further explore the maximum tolerated dose and assess its potential in patients who have discontinued other treatments due to tolerability issues.
Spark’s Take on MTVA Stock
According to Spark, TipRanks’ AI Analyst, MTVA is a Underperform.
MetaVia’s stock score is heavily impacted by its poor financial performance, with persistent losses and no revenue. Despite positive trial results offering some promise, the stock remains high-risk due to negative valuation metrics and weak technical indicators.
To see Spark’s full report on MTVA stock, click here.
More about MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin analogue functioning as a dual agonist for glucagon-like peptide-1 and glucagon receptors, potentially offering superior weight loss compared to selective GLP1R agonists.
YTD Price Performance: -65.31%
Average Trading Volume: 462,671
Technical Sentiment Signal: Buy
Current Market Cap: $6.34M
For a thorough assessment of MTVA stock, go to TipRanks’ Stock Analysis page.